XASX
RHY
Market cap17mUSD
Oct 09, Last price
0.08AUD
1D
4.17%
1Q
-17.58%
IPO
-76.19%
Name
Rhythm Biosciences Ltd
Chart & performance
P/E
—
P/S
311.00
EPS
—
Div yield, %
—
Shrs. gr., 5y
12.53%
Rev. gr., 5y
-40.13%
Revenues
85k
-97.33%
Net income
-6m
L+54.86%
CFO
-5m
L+79.13%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Rhythm Biosciences Limited functions as a forward-thinking enterprise focused on predictive cancer diagnostics, active across both Australian and global territories. The company's core operations involve the creation, advancement, and market introduction of cutting-edge medical diagnostic technologies. A key innovation is ColoSTAT, their specialized blood test designed for the prompt and reliable identification of colorectal cancer. Established in 2017, the firm's main offices are located in Parkville, Australia.
Key people
Gavin Fox-Smith
Chairman of the Board · since 2025
David Atkins
Chief Executive Officer, Managing Director, Director · since 2024
Guy Carisbrooke
Financial Controller · since 2023
Elena Deak
Chief Commercial Officer · since 2022
James Barrie
Joint Company Secretary · since 2024
Andrea Steele
General Counsel, Joint Company Secretary · since 2022
Headquarters & legal address
C/O Bio21 Institute,30 Flemington Road,PARKVILLE
Melbourne, VIC 3052
AU
Melbourne, VIC 3052
AU
Valuation
Title AUD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑08 | 2017‑06 | |
| Income | |||||||||||
Revenues | |||||||||||
Cost of revenue | |||||||||||
Unusual Expense (Income) | |||||||||||
NOPBT | |||||||||||
NOPBT Margin | |||||||||||
Operating Taxes | |||||||||||
Tax Rate | |||||||||||
NOPAT | |||||||||||
Net income | |||||||||||
Dividends | |||||||||||
Dividend yield | |||||||||||
Proceeds from repurchase of equity | |||||||||||
BB yield | |||||||||||
| Debt | |||||||||||
Debt current | |||||||||||
Long-term debt | |||||||||||
Deferred revenue | |||||||||||
Other long-term liabilities | |||||||||||
Net debt | |||||||||||
| Cash flow | |||||||||||
Cash from operating activities | |||||||||||
CAPEX | |||||||||||
Cash from investing activities | |||||||||||
Cash from financing activities | |||||||||||
FCF | |||||||||||
| Balance | |||||||||||
Cash | |||||||||||
Long term investments | |||||||||||
Excess cash | |||||||||||
Stockholders' equity | |||||||||||
Invested Capital | |||||||||||
ROIC | |||||||||||
ROCE | |||||||||||
| EV | |||||||||||
Common stock shares outstanding | |||||||||||
Price | |||||||||||
Market cap | |||||||||||
EV | |||||||||||
EBITDA | |||||||||||
EV/EBITDA | |||||||||||
Interest | |||||||||||
Interest/NOPBT | |||||||||||